Roche's Ocrelizumab Strengthens Lead In Primary Progressive MS
This article was originally published in Scrip
Sufferers of primary progressive multiple sclerosis (PPMS) - the rarer form of the neurological condition for which there is still no approved treatment - have had their hopes boosted by news Roche's CD20 antibody ocrelizumab won breakthrough therapy designation from the FDA, the first investigational therapy to do so in MS.
You may also be interested in...
US FDA extends review timeline for the multiple sclerosis BLA until March 28, 2017 to have time to review new information about commercial manufacturing process, Roche says.
The development of a plethora of new medicines for multiple sclerosis over the past 10 years is truly remarkable. As well as the dozen or so agents now available to treat relapsing MS, the first potential product for the poorly treated condition, primary progressive MS, is nearing the market.
Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.